The European Medicines Agency’s CHMP issued multiple favorable recommendations this month, endorsing new medicines from companies such as Hansoh and Cytokinetics and recommending recent filings including ImmunityBio’s Anktiva and Cytokinetics’ Myqorzo for EU approval. The committee flagged five new drugs and vaccines at its December meeting, with recommendations now moving to the European Commission for final decisions. The CHMP opinions accelerate market access timelines in Europe and signal regulatory momentum for therapies across oncology, neurology and rare disease spaces. Companies highlighted clinical data packages and unmet‑need positioning in public statements; payers in member states will begin HTA and reimbursement discussions once EU approval follows. For readers: CHMP recommendation is the key scientific opinion preceding the Commission’s authorization steps in the EU.